ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
Volume 0.13M
Average 0.07M
PMN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ProMIS Neurosciences, Inc.NASDAQ: PMN
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $2.74M rose 91.3% year over year, ahead of the +11.4% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 64.0% from the prior quarter. Over 3 fiscal years it compounded at -90.2% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +91.3% holds above the trailing-twelve-month pace of +11.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Selling, General & Admin history
Mixed currencies · from the income statement
- Latest · FY2025
- 6.79M USD
- Year-over-year change
- +9.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.79M | +9.7% |
| FY2024 | 2024-12-31 | 6.19M | -3.0% |
| FY2023 | 2023-12-31 | 6.38M | — |
| FY2022 | 2022-12-31 | 7.29B | +220000.8% |
| FY2021 | 2021-12-31 | 3.31M | — |
Selling, General & Admin vs competitors
How PMN compares with its peers on the latest reported figures
- PMN's LTM Jun 2026 selling, general & admin of $7.78M is the 3rd highest of the 4 companies compared; the peer median is $14.78M.
- Its year-over-year change of +11.4% is the lowest of 3, against a peer median of +94.5%.
- Over three fiscal years its annual growth of -90.2% compares with a peer median of -5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.63M | +164.2% | +95.7% | — | |
| LTM Jun 2024 | $14.78M | — | -14.4% | 227.7% | |
| LTM Jun 2026 | $7.78M | +11.4% | -90.2% | — | |
| LTM Mar 2026 | $4.96M | +24.9% | -5.5% | — | |
| Peer median (excluding PMN) | $14.78M | +94.5% | -5.5% | 227.7% | |
Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 16.68K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 5.85M | 0 | 10.44M | 0 | 0 |
| Gross Profit | (5.84M) | 0 | (10.44M) | 0 | 0 |
| Gross Margin | -35031.9% | — | — | — | — |
| Research & Development | 4.95M | 16.09B | 7.88M | 10.64M | 33.38M |
| Selling, General & Admin | 3.31M | 7.29B | 6.38M | 6.19M | 6.79M |
| Operating Expenses | 4.63M | 23.38B | 8.45M | 16.83M | 40.17M |
| Depreciation & Amortization | 45.83K | 0 | 28.04K | 0 | 0 |
| EBITDA | (9.33M) | (17.78B) | (17.81M) | 2.86M | (39.72M) |
| EBITDA Margin | -55923.2% | — | — | — | — |
| Operating Income | (10.57M) | (23.38B) | (18.9M) | (16.83M) | (40.17M) |
| Operating Margin | -63350.5% | — | — | — | — |
| Interest Income | 4.73K | 0 | 0 | 0 | 0 |
| Interest Expense | 416.29K | 282.06M | 201.39K | 76.78K | 0 |
| Other Income / Expenses | (1.91M) | 5.32B | 1.39M | 19.61M | 448.16K |
| Income Before Tax | (12.48M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Pre-Tax Margin | -74804.2% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (11.98M) | (18.06B) | (17.51M) | 2.78M | (39.72M) |
| Net Margin | -71819.3% | — | — | — | — |
| EPS (Basic) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| EPS (Diluted) | (51.77) | (60.25) | (35.50) | 2.75 | (22.61) |
| Weighted Avg Shares | 231.42K | 300.1K | 491.71K | 1.04M | 1.76M |
| Weighted Avg Shares (Diluted) | 231.43K | 300.1K | 491.71K | 1.06M | 1.76M |
ProMIS Neurosciences, Inc.
NASDAQ:PMN
Intrinsic Alpha fair value
Locked
Current Price
$11.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.